• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Financial Navigation Programs Are ‘Efficient’ for Some With Multiple Myeloma

by | Dec 12, 2023 | Uncategorized

Source: CureToday articles Study findings support the use of a financial navigation program, in hopes of aiding patients with multiple myeloma affected by financial toxicity. Read More

Reduced talquetamab dose intensity maintains efficacy, may lessen toxicities in myeloma

by | Dec 12, 2023 | Uncategorized

SAN DIEGO — Reduced-intensity dosing of talquetamab may improve tolerability without compromising efficacy among patients with relapsed or refractory multiple myeloma, according to study results.Most patients in the phase 1/phase 2 MonumenTAL-1 study who responded to...

Abecma May Improve Quality of Life in Previously Treated Myeloma

by | Dec 10, 2023 | Uncategorized

Source: CureToday articles The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens. Read More

Tecvayli Outcomes Similar in Clinic And Trials for R/R Myeloma

by | Dec 9, 2023 | Uncategorized

Source: CureToday articles Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma. Read More

Multiple myeloma regimens significantly less effective in real-world treatment settings

by | Dec 9, 2023 | Uncategorized

SAN DIEGO — Standard care treatments for multiple myeloma conferred markedly shorter survival benefits in real-world settings, study results presented at ASH Annual Meeting and Exposition showed.Data from a retrospective analysis revealed that six of seven standard...

Side Effects of Bone Strengtheners: Multiple Myeloma

by | Dec 2, 2023 | Uncategorized

Source: CureToday articles I didn’t know that a side effect of bone strengtheners could be jawbone detachment. Read More
« Older Entries
Next Entries »

Recent Content

  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT